Welcome to our dedicated page for GEMINA LABORATORIES news (Ticker: GLABF), a resource for investors and traders seeking the latest updates and insights on GEMINA LABORATORIES stock.
Gemina Laboratories Ltd (GLABF) is a biosensor and diagnostic company specializing in transformative, patented, proprietary chemistry that powers next-generation testing platforms for various pathogens affecting human health. The company's technology enables fast, affordable, accurate, and easily self-administered testing platforms. With a product pipeline that includes rapid testing for COVID-19, influenza, tuberculosis (TB), and other viruses, Gemina Labs is at the forefront of innovative diagnostics technology.
Gemina Laboratories (CSE:GLAB, OCTQB:GLABF) has announced a non-brokered private placement offering of up to 9,333,333 common shares at $0.75 per share, aiming to raise gross proceeds of up to $7,000,000. The funds will be used to accelerate platform development, expand production, support business development and commercialization activities, and provide working capital. The securities issued will have a four-month and one-day statutory hold period in Canada.
Gemina Laboratories has provided a strategic update for H1 2024, highlighting key achievements and future plans. The company signed its first license deal with a global diagnostics company in April, signaling commercial validation. It is also in advanced discussions with four other significant diagnostics firms. In June, Gemina issued its first commercial invoice, with revenues expected to ramp up in 2025. The company continues to innovate, with a strong R&D team developing new products and solutions. Gemina's new protein production facility is set to open in August, and the company has expanded its market presence to the U.S. by listing on the OTCQB under ticker GLABF.
Gemina Laboratories (OTCQB: GLABF) has commenced trading on the OTCQB Venture Market in the United States. This move aims to expand the company's investor reach, build visibility, increase liquidity, and diversify its shareholder base. Gemina's shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol 'GLAB' and the Frankfurt Exchange under '817'. CEO Brian Firth is optimistic that this expansion will complement their existing listings and facilitate a streamlined approach for US investors to trade their shares. Investors can access real-time quotes and financial disclosures on the OTC Markets website.
Gemina Laboratories Ltd. (CSE:GLAB, OTC:GLABF) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. CEO Brian Firth will present both virtually and in-person, with the presentation available online starting at 7:00 a.m. EST. Gemina specializes in biosensor technology and diagnostics, focusing on rapid testing for pathogens affecting health, including COVID-19. A replay of the presentation will be accessible for 30 days.
Gemina Laboratories Ltd. (CSE:GLAB, OTC:GLABF) has appointed Brian Firth as its new Chief Executive Officer, transitioning from an R&D focus to a revenue-driven model. Firth, with extensive experience in point-of-care diagnostics, previously held leadership roles at Swiss Precision Diagnostics and founded The Health Works Ltd. His appointment is viewed as a significant step towards growth, with plans to launch revenue-generating products. Concurrently, founding CEO John Davies becomes Chairman of the Board. Firth's stock options include performance milestones and a vesting schedule starting September 7, 2023.
FAQ
What is the current stock price of GEMINA LABORATORIES (GLABF)?
What is the market cap of GEMINA LABORATORIES (GLABF)?
What is Gemina Laboratories Ltd known for?
What kind of testing platforms does Gemina Labs offer?
What makes Gemina Labs' technology unique?
What is Gemina Labs' objective?
Where can investors find more information about Gemina Laboratories Ltd?
How can investors stay updated with the latest news from Gemina Laboratories?
What marketplaces are Gemina Laboratories shares traded on?
Who is the CEO of Gemina Laboratories Ltd?
What is the mission of Gemina Laboratories?
How can interested parties contact Gemina Laboratories?
What sets Gemina Laboratories apart from other companies in the industry?
Why should investors consider Gemina Laboratories for their portfolio?
